Trial Profile

Healing Effect of Gastric mucosal Lesion of patient with Osteoarthritis or Rheumatism by Cox2-Inhibitor and Anti ulcer agent(Rebamipide) combination therapy.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 May 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rebamipide (Primary) ; Celecoxib
Indications Back pain; NSAID-induced ulcer; Osteoarthritis; Rheumatoid arthritis
Focus Adverse reactions; Therapeutic Use
Acronyms GLORIA

Most Recent Events

22 May 2012 Results presented at Digestive Disease Week 2012.
18 Jun 2011 Actual end date is 1 Jun 2011 according to University Hospital Medical Information Network - Japan.
18 Jun 2011 Status changed from recruiting to completed according to University Hospital Medical Information Network - Japan.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com